Excitement is permeating the biopharmaceutical community as single nucleotide polymorphisms (SNPs) continue to demonstrate promising results in the practice of molecular medicine. SNPs identification offers the most information-dense, cost-effective system for analyzing and characterizing genetic variety (i.e., for correlating genotype with phenotype). Strategic Overview of the SNPs Landscape is a new DR Report published by Decision Resources, Inc., that focuses on the highly active area of SNPs and provides a strategic as well as technological overview of this emerging landscape.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION)

Individuals possess many traits that are biologically "silent," meaning that they do not impart susceptibility or resistance to a disease. Other traits have biological significance and may in fact determine disease susceptibility. The SNP characterization effort focuses on providing molecular markers (SNPs) that are associated with these biological susceptibilities. A major thrust of SNPs research is focused on their association with disease and, therefore, their role as markers defining populations that exhibit a given phenotype. A SNP is a molecular tool that can be used to achieve the goal of pharmacogenomics: the exploitation of genetic diversity for drug discovery and development. Once a biological phenotype is correlated with a set of SNPs that are associated with certain traits, patient stratification can be performed easily to administer the therapeutic agent only to those individuals who respond to the agent and in whom it shows no toxicity.

Strategic Overview of the SNPs Landscape provides a picture of the market opportunity afforded to the pharmaceutical industry by virtue of the interest in and future use of SNPs. Having framed the strategic elements and the opportunities in SNPs, the report then analyzes the technological elements of the market opportunity: the ability to genotype large numbers of individuals across the vast number of SNPs being discovered. The report focuses on the various technological approaches and their features and benefits, including an analysis of the strengths, weaknesses, opportunities, and threats (SWOT) of each approach. This technological discussion is key to pharmaceutical, biotechnology, and technology/tool companies that seek to either deploy these genotyping systems or provide their own solutions in this growing market.

Contact: Jean Carbone, 781.487.3737 (telephone), 781.487.3735 (fax), or carbone@dresources.com (e-mail). In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or fbidart@decisionresources.be (e-mail). In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp (e-mail). http://www.dresources.com

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends.

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 201-369-3467

SOURCE: Decision Resources, Inc.

Contact: Cindy Ohlman of Decision Resources, 781-487-3721,

Decision Resources Report Evaluates the Activity of 20 Companies Developing Products Based on the Modulation of Cell-Signal Pathways

View Now